恒生前海沪港深新兴产业精选混合：2025年第二季度利润227.11万元 净值增长率4.18%

Core Viewpoint - The AI Fund Hang Seng Qianhai Hong Kong-Shanghai Emerging Industry Selected Mixed Fund (004332) reported a profit of 2.2711 million yuan for Q2 2025, with a weighted average profit per fund share of 0.0446 yuan. The fund's net value growth rate was 4.18%, and the fund size reached 56.6848 million yuan by the end of Q2 2025 [3][14]. Fund Performance - As of July 17, the fund's unit net value was 1.166 yuan. The fund manager, Xing Cheng, currently manages four funds. The Hang Seng Qianhai High-end Manufacturing Mixed A fund had the highest one-year growth rate at 38.68%, while the Hang Seng Qianhai Hong Kong-Shanghai Emerging Industry Selected Mixed Fund had the lowest at 16.15% [3]. - The fund's performance over different time frames includes a three-month growth rate of 12.63%, a six-month growth rate of 10.71%, a one-year growth rate of 16.15%, and a three-year growth rate of -38.20% [4]. Risk Metrics - The fund's Sharpe ratio over the past three years was -0.4274, ranking 284 out of 319 comparable funds [8]. - The maximum drawdown over the past three years was 54.08%, with the largest single-quarter drawdown occurring in Q1 2024 at 29.78% [10]. Investment Strategy - The fund maintained an average stock position of 89.57% over the past three years, higher than the comparable average of 83.13%. The fund reached its highest stock position of 94.03% at the end of Q1 2025 and its lowest at 69.98% at the end of 2022 [13]. - The fund manager anticipates a market characterized by fluctuations and structural opportunities, with limited macro policy support. The focus is on thematic and value assets that are less correlated with macroeconomic cycles, which may benefit from lower discount rates and liquidity overflow [3]. Top Holdings - As of the end of Q2 2025, the fund's top ten holdings included Shenghong Technology, Dongpeng Beverage, Lanke Technology, Chuanfeng Power, New Strong Union, Daotong Technology, Pudong Development Bank, Longxin General, Daikin Heavy Industry, and Haoyuan Pharmaceutical [17].